Clinical Trial Detail

NCT ID NCT02955290
Title CIMAvax Vaccine and Nivolumab in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Roswell Park Cancer Institute
Indications

lung non-small cell carcinoma

Therapies

CIMAvax-EGF + Nivolumab

Age Groups: senior adult

No variant requirements are available.